Tyra Biosciences, Inc. (TYRA)
NASDAQ: TYRA · Real-Time Price · USD
31.60
+0.54 (1.74%)
Jul 21, 2026, 2:10 PM EDT - Market open
Tyra Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 84.96 | 77.39 | 91.97 | 58.01 | 251.21 | 302.18 |
Short-Term Investments | 298.51 | 178.62 | 249.48 | 145.46 | - | - |
Cash & Short-Term Investments | 383.47 | 256 | 341.44 | 203.47 | 251.21 | 302.18 |
Cash Growth | 20.23% | -25.02% | 67.81% | -19.00% | -16.87% | 1884.90% |
Other Current Assets | 11.15 | 9.45 | 6.02 | 8.2 | 6.08 | 1.88 |
Total Current Assets | 394.61 | 265.45 | 347.46 | 211.67 | 257.29 | 304.06 |
Net Property, Plant & Equipment | 6.66 | 6.89 | 7.72 | 8.15 | 3.54 | 2.09 |
Other Long-Term Assets | 10.77 | 10.27 | 8.38 | 6.03 | 5.35 | 0.56 |
Total Assets | 412.04 | 282.61 | 363.56 | 225.86 | 266.18 | 306.7 |
Accounts Payable | 3.64 | 1.18 | 0.59 | 4.66 | 1.15 | 0.6 |
Accrued Expenses | 15.13 | 16.44 | 13.59 | 10.39 | 4.42 | 2.82 |
Current Portion of Leases | 0.49 | 0.47 | 0.41 | 0.28 | 0.14 | 0.2 |
Total Current Liabilities | 19.26 | 18.09 | 14.59 | 15.33 | 5.7 | 3.62 |
Long-Term Leases | 5.21 | 5.34 | 5.81 | 6.22 | 2.48 | 0.98 |
Other Long-Term Liabilities | - | - | 0 | 0.05 | 0.17 | 0.37 |
Total Long-Term Liabilities | 5.21 | 5.34 | 5.81 | 6.26 | 2.65 | 1.35 |
Total Liabilities | 24.47 | 23.43 | 20.41 | 21.6 | 8.35 | 4.96 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
Additional Paid-in Capital | 798.03 | 630.04 | 593.69 | 368.71 | 353.52 | 342.1 |
Accumulated Other Comprehensive Income | 0.11 | 0.39 | 0.77 | 0.38 | - | - |
Retained Earnings | - | -371.26 | -251.31 | -164.83 | -95.7 | -40.37 |
Total Common Shareholders' Equity | 387.58 | 259.18 | 343.15 | 204.26 | 257.83 | 301.74 |
Shareholders' Equity | 387.58 | 259.18 | 343.15 | 204.26 | 257.83 | 301.74 |
Total Liabilities & Equity | 412.04 | 282.61 | 363.56 | 225.86 | 266.18 | 306.7 |
Total Debt | 5.7 | 5.81 | 6.22 | 6.5 | 2.62 | 1.18 |
Net Cash (Debt) | 377.77 | 250.19 | 335.22 | 196.97 | 248.59 | 301 |
Net Cash Growth | 50.99% | -25.36% | 70.19% | -20.76% | -17.41% | 1895.75% |
Net Cash Per Share | 6.28 | 4.20 | 5.86 | 4.61 | 5.93 | 21.84 |
Book Value | 387.58 | 259.18 | 343.15 | 204.26 | 257.83 | 301.74 |
Book Value Per Share | 6.44 | 4.35 | 6.00 | 4.78 | 6.16 | 21.90 |
Tangible Book Value | 387.58 | 259.18 | 343.15 | 204.26 | 257.83 | 301.74 |
Tangible Book Value Per Share | 6.44 | 4.35 | 6.00 | 4.78 | 6.16 | 21.90 |